PRODUCT DESCRIPTION
The enzyme D016 is a patented bacterial hyaluronidase with exceptionally high enzymatic activity (≥ 1.2 million IU/mg) and purity (> 97 %). D016 is our innovative enzyme that, for the first time, combines the unique mechanisms of PH20 and HYAL4. This enables it to efficiently break down both classical hyaluronic acid and particularly resilient chondroitin sulphate-containing tissue structures, and, through the body’s natural regenerative processes, restore the physiological remodelling of the extracellular matrix (ECM).
With a specific activity approximately 15–2,000 times higher than known hyaluronidase products, D016 sets new standards in enzymatic matrix degradation. At the same time, it offers a clear safety advantage: because D016 is not PEGylated, it avoids the well-known risks associated with PEGylated enzymes. D016 therefore combines maximum performance with excellent user safety and convenience – enabling innovative applications in cosmetics, medicine, and research.
GLOBAL AVAILABILITY – THE NEW GENERATION OF HYALURONIDASE
GMP-like or GMP-grade
Produced in Germany to GMP-like or GMP-grade standards, D016 offers several advantages over ALT-B4, bovine, or human hyalase. Production capacity is scalable and, since early 2025, available in two manufacturing grades for pharmaceutical and cosmetic development:
-
GMP-like: for research and galenic formulation development
-
GMP-grade: for clinical and regulatory pharmaceutical applications
Current production capacity:
-
2,000 mg GMP-like every 6 months
-
500 mg GMP-grade every 9 months
Areas of application are for example:
- Drug development (atherosclerosis, oncological infiltrates, subcutaneous active ingredients)
- Cosmetic penetration enhancement (dermatological & aesthetic)
- Combination with liposomes, biologics, NAD+, vitamin preparations etc.
TECHNOLOGICAL ADVANTAGE
D016 is based on a modified bacterial sequence and therefore presents no relevant risk of immunogenicity. It achieves significantly higher enzymatic activity than ALT-B4 and is completely free from animal-derived components – eliminating the need for complex humanisation.
Thanks to its unique substrate specificity, D016 offers targeted benefits in the treatment of microangiopathic tissue alterations.
Pharmact Pharmaceuticals GmbH
– Your Partner for D016
As a subsidiary based in Saarland, Pharmact Pharmaceuticals GmbH is your direct point of contact for D016 production, logistics, and distribution. Benefit from our in-depth product expertise and our dedicated specialist sales team.
Find out more about the possible applications of D016 or arrange a meeting with our sales team – simply via our Contact form.